Most guidelines advocate a platelet transfusion in patients with a platelet count of <30 50 × 10/l accompanied by bleeding or at high risk for bleeding, and in patients with a platelet count <10 × 10/l, regardless of the presence or absence of bleeding.
Most guidelines advocate to use the difference between the highest sCr value over a certain time span, and a pre admission historical baseline value [ 15, 16] or an estimated sCr value by solving the MDRD formula assuming a GFR of 75 ml/min/1,73 m [ 17– 20].
Most guidelines, therefore, advocate calcium and vitamin D supplements, bisphosphonates, and eventually teriparatide as a second choice because of its higher cost price in the prevention of GIOP in patients at high risk, such as those with persistent disease activity, high dose of GCs, or high background risk such as menopause, age, low BMD, and the presence of clinical risk factors [ 138, 139].
Together with previous findings, this constitutes evident support to the less strict approach to metformin treatment in patients with renal impairment, advocated in most guidelines.
23 In conclusion, current guidelines advocate for VTE prophylaxis among most medical patients, despite the fact that they only have a 1%2%% risk of developing VTE.
Among the interventions advocated to assist in achieving these targets, most guidelines recommend a reduced intake of salt, as dietary sodium intake is positively correlated with blood pressure levels in the general population (1).
Asthma guidelines advocate maintaining asthma control while minimizing corticosteroid exposure.
Incidence of inadvertent perioperative hypothermia is still high; therefore, present guidelines advocate "prewarming" for its prevention.
While published guidelines advocate early diagnosis and prompt treatment of renal disease [ 2], it is not clear at what point direct referral to a nephrologist is the most efficient management strategy for patients with renal difficulties.
The treatment guidelines are similar to those by the BTS, although the ATS guidelines advocate macrolide-containing regimens (5 ).
Consensus guidelines advocate continuation of maintenance immunosuppression for at least 18 to 24 months [ 27, 53].
